FDC Ltd. has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Timolol Maleate Ophthalmic Solution. Timolol Maleate Ophthalmic Solution is a nonselective beta-blocking drug, used as a primary line of treatment for glaucoma.

According to a report in Archives of Ophthalmology, black patients have a higher risk of death from a cardiac disease if they suffer from high pressure in the eyes or have been diagnosed with glaucoma at some point. The study was conducted by Suh-Yuh Wu, M.A., of Stony Brook University, Stony Brook, New York, and other colleagues, and focused mainly on black patients.

ScyFix has developed a device that treats eye diseases, such as glaucoma and macular degeneration, with electric currents. The clinical trials are currently underway in India and the U.S. The company hopes to be the first to introduce an FDA approved device designed to restore eyesight. Until now, the use of electricity to slow or even reverse the effects of eye diseases has never made it out of a laboratory, said Dr. Thomas Samuelson, a founding partner of Minnesota Eye Consultants.